Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Depreciation & Amortization (CF) of $110000.0 for Q1 2026, down 37.5% year-over-year from $176000.0 in Q1 2025, and down 6.78% quarter-over-quarter from $118000.0 in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $110000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 37.5% year-over-year to $110000.0; the TTM figure through Mar 2026 stood at $555000.0 (down 1.94% YoY), while the FY2025 annual figure was $621000.0, up 16.29% from the prior year.
- Depreciation & Amortization (CF) declined to $110000.0 in Q1 2026 per LXRX's latest filing, from $118000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $176000.0 in Q1 2025 and bottomed at $103000.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $132117.6 across 5 years, with a median of $126000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 194.59% — and 2026, when it slumped 37.5%.
- Lexicon Pharmaceuticals' Depreciation & Amortization (CF) stood at $103000.0 in 2022, then soared by 42.72% to $147000.0 in 2023, then retreated by 14.97% to $125000.0 in 2024, then declined by 5.6% to $118000.0 in 2025, then slipped by 6.78% to $110000.0 in 2026.
- Business Quant data shows LXRX's Depreciation & Amortization (CF) at $110000.0 in Q1 2026, $118000.0 in Q4 2025, and $151000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | 102,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 102,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 139,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 147,000.00 |
| Sep 30, 2023 | 151,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Mar 31, 2023 | 112,000.00 |
| Dec 31, 2022 | 103,000.00 |
| Sep 30, 2022 | 108,000.00 |
| Jun 30, 2022 | 107,000.00 |
| Mar 31, 2022 | 109,000.00 |
| Dec 31, 2021 | 112,000.00 |
| Sep 30, 2021 | 101,000.00 |